A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose

ID Number 15-2244

Principal Investigator(s)
John O Mascarenhas

Department(s) or Division(s)
Hematology and Medical Oncology


You have been asked to take part in this study because you have been diagnosed with myelofibrosis and your cancer has returned after treatment with a Janus Kinase (JAK) Inhibitor.  Myelofibrosis is a type of cancer that affects the production of blood cells.

The purpose of this study is to find the dose of imetelstat that best treats myelofibrosis. The effects of imetelstat on myelofibrosis as well as any side effects will be explored.

Contact Information
Carrie Newsom
(212) 824-7309

Recruiting Patients: Yes